ReviewGastroenterology and hepatology from bed to bench2025
Global prevalence and incidence of inflammatory bowel disease: a systematic review and meta-analysis of population-based studies.
Review in Gastroenterology and hepatology from bed to bench, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Non-invasive Molecular Diagnostics for Inflammatory Bowel Disease : A Genetic and Biomarkers Study
The Effect of Palmitoylethanolamide on the Clinical Outcomes in Ulcerative Colitis Patients
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparative efficacy of dietary interventions and enteral nutrition in adults with ulcerative colitis: a network meta-analysis.Frontiers in nutrition · 2026Pooled it
- Adalimumab Therapy for Crohn's Disease and Axial Spondyloarthritis in Latent Tuberculosis:Sultan Qaboos University medical journal · 2026Pooled it
- Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Olamkicept up to 2400 mg in Healthy Men: Phase I, Randomized, Placebo-Controlled, and Double-Blind Trial.Clinical and translational science · 2026Trial
- Enhanced antitumor efficacy of sulfasalazine and mesalazine in colorectal cancer through modulatory action of Lacticaseibacillus rhamnosus GG.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Factors Affecting the Adherence to Partial Enteral Nutrition Combined with the Crohn's Disease Exclusion Diet in Crohn's Disease Adult Patients.Healthcare (Basel, Switzerland) · 2026Article
- Association of Dietary Components and Combined Dietary Profiles with Ulcerative Colitis: A Case-Control Study.Diseases (Basel, Switzerland) · 2026Article
- Dietary Adjuvanticity in the Modern Plant Exposome: Implications for Immune-Mediated Inflammatory Diseases.Nutrients · 2026Review
- Integrated Multi-Omics Analysis of Antarctic Krill Oil in Alleviating DSS-Induced Colitis and Modulating Gut Microbiota in Mice.Marine drugs · 2026Article
- Phytotherapeutic potential of Gossypium barbadense L. root as an alternative therapy for colitis: a comprehensive review with network pharmacology insights.Inflammopharmacology · 2026Review
- Review
- Real-World Safety and Herpes Zoster Outcomes After Recombinant Zoster Vaccination in Inflammatory Bowel Disease.Journal of clinical medicine · 2026Article
- Attentional variability as a cognitive marker of clinical activity in Crohn's disease.Crohn's & colitis 360 · 2026Article
- Cucurbitacin derivatives (B, IIa, IIb, and E): modulating gut dysbiosis and inflammatory pathways for multi-target therapy of ulcerative colitis.Inflammopharmacology · 2026Review
- Elevated caspase 3 expression correlates with severe inflammation in Crohn's disease.European journal of histochemistry : EJH · 2026Article
- DSS Colitis Model: Traps, Tricks, and Reporting Recommendations.Biomedicines · 2026Review
- Generative AI-augmented transcriptomic and microbiome analysis across inflammatory and fibrotic disease states in Crohn's disease.Frontiers in artificial intelligence · 2026Article
- Elevated TFR1 is associated with inflammatory burden and ferroptosis in ulcerative colitis.Frontiers in medicine · 2026Article
- Probiotic drug interactions in ulcerative colitis: a microbiota and metabolite perspective.Frontiers in microbiology · 2026Review
- Tracheobronchial stenosis as a rare extraintestinal manifestation of ulcerativecolitis: a case series with different therapeutic approaches.Frontiers in medicine · 2026Article
- Dermatological and gastrointestinal adverse reactions in ocrelizumab treated patients with multiple sclerosis: a case series.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The aim of this study was to systematically review the global epidemiology of Inflammatory Bowel Disease (IBD). Background: IBD is a global concern, and its incidence is rising worldwide. Methods: We searched PubMed, Scopus, and Web of Science from 1 January 2000 to 14 July 2022 using MeSH keywords. All population-based studies that reported the incidence or prevalence of IBD, Crohn's disease (CD), or ulcerative colitis (UC) were included. Random effect models were applied to combine the prevalence and incidence. Results: Findings from 215 studies were analyzed. The global prevalence rates of IBD, CD, and UC were 229.7 per 100,000 (95% confidence interval: 212.4 to 247.0), 84.2 (78.5 to 89.9), and 120.4 (110.5 to 130.3), and the incidence was 9.7 per 100,000 person-years (9.2 to 10.2), 4.0 (3.8 to 4.2), and 5.0 (4.6 to 5.3), respectively. The highest IBD and CD incidence were seen in Oceania (21.3 [12.9 to 29.7] and 12.2 [8.5 to 15.9], respectively), while the highest incidence of UC was reported in North America (9.8 [6.7 to 12.8]). According to the pooled prevalence, Europe had the highest prevalence rates of IBD and UC (348.4 [315.2 to 381.5] and 198.6 [181.6 to 215.6], respectively), whereas Oceania was the continent with the highest CD prevalence (173.6 [151.8 to 195.4]). Conclusion: Our findings showed that the incidence and prevalence of IBD in both developed and developing nations are mounting. Special focus should be placed on understanding and managing pediatric CD cases, necessitating targeted research and early interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.